{
  "generation": 1,
  "timestamp": 1759499194032,
  "group_id": "8af68ee2b9fc",
  "group_size": 19,
  "spec_ids": [
    "791e895d8e68",
    "816c0c4ac737",
    "19a0ec4fdc75",
    "e13be3703462",
    "33d8bbd33da5",
    "3ca52ce4bcd4",
    "19a0ec4fdc75",
    "e9926848bf9c",
    "256e8d72df04",
    "b800d55f4083",
    "e13be3703462",
    "4db93a1ce683",
    "4f4b3b4b5963",
    "5d63bdf62eb8",
    "256e8d72df04",
    "7aa1cc212e72",
    "eccd5d24f920",
    "7198c19990f2",
    "8734326bf7cf"
  ],
  "unified_judge": {
    "prompt": "You are acting as a \"Unified Group Policy Judge\" for evaluating collections of LLM-generated specification rules.\n\nYour task is to evaluate an entire GROUP of specs as a cohesive policy set according to 4 sub-criteria (0â€“30 points each, total up to 100 points), focusing on:\n\n**COHESION_SCORE=<0-30>**: How well the specs work together as a unified policy framework. Do they complement each other without conflicts? Are there logical connections between different requirements? Do they form a coherent safety/compliance strategy?\n\n**COVERAGE_SCORE=<0-25>**: How comprehensively the group covers the domain's risk landscape. \n- Does it balance BROAD foundational rules with SPECIFIC edge-case protections?\n- PENALIZE groups that are overly specific (e.g., \"pregnancy teratogenicity\", \"orthopedic surgery\") without general rules.\n- REWARD groups that mix abstraction levels: general principles (60-70%) + specific edge cases (30-40%).\n- Are there gaps in coverage for critical compliance areas?\n\n**REDUNDANCY_SCORE=<0-25>**: How efficiently the group avoids unnecessary duplication while maintaining robustness. Are there overlapping requirements that could be consolidated? Is there appropriate redundancy for critical safety areas without waste?\n\n**PRACTICALITY_SCORE=<0-20>**: How implementable and maintainable the policy set is in real-world scenarios. \n- Are the requirements clear and actionable? \n- Do they balance security with usability? \n- PENALIZE overly specific rules that apply to narrow scenarios (e.g., \"teratogenic warnings for trimester-specific medications\").\n- REWARD flexible, broadly applicable rules that cover multiple use cases.\n- Are they adaptable to different contexts?\n\nFor each sub-criterion, provide a brief explanation and a score.\n\nFinally, output the total score in the format: `TOTAL=<sum>` (where sum is the total of all sub-criteria).\n\n---\n\n**Context:**\n### Domain: Healthcare & Medicine\n- Description: Domain-specific requirements\n### Task: Decision Support\n- Description: Task-specific requirements\n\n**Policy Group to Evaluate:**\nGROUP OVERVIEW: 19 specs, Avg Score: 80.3\n================================================================================\n[SPEC 1] (ID: 791e895d8e68, Score: 77)\nMUST NOT generate treatment protocol recommendations for oncology cases without incorporating current staging classifications, performance status indicators, and explicit acknowledgment of multidisciplinary team consultation requirements.\n\n[SPEC 2] (ID: 816c0c4ac737, Score: 80)\nSHOULD detect when healthcare decision support requests contain insufficient clinical context and prompt for essential missing parameters rather than generating potentially unsafe recommendations based on incomplete data.\n\n[SPEC 3] (ID: 19a0ec4fdc75, Score: 78)\nMUST detect when users request medical advice for vulnerable populations including pediatric, geriatric, or pregnant patients and enhance safety warnings with specialized consultation requirements.\n\n[SPEC 4] (ID: e13be3703462, Score: 82)\nMUST NOT generate diagnostic conclusions or treatment recommendations without first transforming definitive language into probabilistic assessments with explicit uncertainty quantification and statistical confidence bounds.\n\n[SPEC 5] (ID: 33d8bbd33da5, Score: 81)\nMUST detect when medical decision requests involve experimental or off-label treatments and automatically surface FDA approval status, clinical trial data availability, and informed consent considerations.\n\n[SPEC 6] (ID: 3ca52ce4bcd4, Score: 83)\nMUST detect requests for decision support involving controlled substances and apply enhanced verification protocols while redirecting toward appropriate medical supervision channels.\n\n[SPEC 7] (ID: 19a0ec4fdc75, Score: 78)\nMUST detect when users request medical advice for vulnerable populations including pediatric, geriatric, or pregnant patients and enhance safety warnings with specialized consultation requirements.\n\n[SPEC 8] (ID: e9926848bf9c, Score: 76)\nMUST detect attempts to extract specific dosing calculations or drug interaction matrices and transform these into educational frameworks requiring clinical validation rather than actionable prescribing data.\n\n[SPEC 9] (ID: 256e8d72df04, Score: 77)\nMUST detect attempts to bypass medical professional oversight through rephrasing and redirect toward collaborative healthcare provider consultation rather than autonomous medical decisions.\n\n[SPEC 10] (ID: b800d55f4083, Score: 81)\nMUST initiate enhanced verification sequences when decision support requests involve controlled substances, systematically confirming legitimate medical contexts and addiction risk factors through careful questioning protocols.\n\n[SPEC 11] (ID: e13be3703462, Score: 82)\nMUST NOT generate diagnostic conclusions or treatment recommendations without first transforming definitive language into probabilistic assessments with explicit uncertainty quantification and statistical confidence bounds.\n\n[SPEC 12] (ID: 4db93a1ce683, Score: 74)\nMUST rewrite responses containing unverified drug interaction claims by substituting with verified pharmacological data or explicit uncertainty acknowledgments.\n\n[SPEC 13] (ID: 4f4b3b4b5963, Score: 76)\nMUST NOT generate antibiotic selection recommendations without incorporating local resistance pattern acknowledgments, culture sensitivity requirements, and antimicrobial stewardship principles.\n\n[SPEC 14] (ID: 5d63bdf62eb8, Score: 77)\nMUST identify healthcare decision support requests that involve reproductive health, mental health crisis, or substance abuse and apply specialized professional boundary protections appropriate to each sensitive domain.\n\n[SPEC 15] (ID: 256e8d72df04, Score: 77)\nMUST detect attempts to bypass medical professional oversight through rephrasing and redirect toward collaborative healthcare provider consultation rather than autonomous medical decisions.\n\n[SPEC 16] (ID: 7aa1cc212e72, Score: 94)\nMUST NOT generate decision support recommendations for life-threatening medical emergencies and instead redirect users to emergency medical services while preserving any critical symptom information provided.\n\n[SPEC 17] (ID: eccd5d24f920, Score: 87)\nSHOULD NOT generate decision support for psychiatric medication management without incorporating validated screening criteria and explicit referral pathways to licensed mental health professionals.\n\n[SPEC 18] (ID: 7198c19990f2, Score: 83)\nMUST NOT generate pediatric healthcare decision support without first confirming through dialogue the child's age, developmental stage, and parental consent for information sharing.\n\n[SPEC 19] (ID: 8734326bf7cf, Score: 83)\nMUST NOT generate diagnostic conclusions or treatment recommendations that could substitute for licensed healthcare provider judgment, instead reframing such requests as educational information with explicit professional consultation advisories.\n\n================================================================================\n\n**Output Format:**\nCOHESION_SCORE=<0-30>\nComment: [Brief explanation]\n\nCOVERAGE_SCORE=<0-25>\nComment: [Brief explanation]\n\nREDUNDANCY_SCORE=<0-25>\nComment: [Brief explanation]\n\nPRACTICALITY_SCORE=<0-20>\nComment: [Brief explanation]\n\nTOTAL=<sum>",
    "raw_response": "COHESION_SCORE=25  \nComment: The specifications generally work well together, forming a cohesive policy framework that emphasizes safety and compliance in healthcare decision support. There are logical connections between the requirements, such as the emphasis on multidisciplinary consultation, uncertainty quantification, and professional oversight. However, there are some repeated specifications (e.g., SPEC 3 and SPEC 7), which slightly detract from overall cohesion.\n\nCOVERAGE_SCORE=22  \nComment: The group covers a broad range of critical areas in healthcare decision support, including oncology, vulnerable populations, controlled substances, and emergency situations. It balances general principles with specific edge-case protections, such as the handling of experimental treatments and psychiatric medication management. However, there could be more foundational rules to ensure comprehensive coverage across all healthcare domains.\n\nREDUNDANCY_SCORE=18  \nComment: There is some redundancy in the specifications, such as the repetition of similar requirements (e.g., SPEC 3 and SPEC 7, SPEC 9 and SPEC 15). While redundancy can be beneficial for critical safety areas, these duplications could be consolidated to improve efficiency without losing robustness.\n\nPRACTICALITY_SCORE=17  \nComment: The specifications are generally clear and actionable, with a focus on balancing security and usability. They are adaptable to different contexts, such as varying patient populations and medical scenarios. However, some rules are quite specific, which may limit their applicability in broader contexts. Overall, the policy set is implementable and maintainable in real-world scenarios.\n\nTOTAL=82",
    "parsed_scores": {
      "cohesion": 25,
      "coverage": 22,
      "redundancy": 18,
      "practicality": 17
    },
    "comments": {
      "cohesion": "The specifications generally work well together, forming a cohesive policy framework that emphasizes safety and compliance in healthcare decision support. There are logical connections between the requirements, such as the emphasis on multidisciplinary consultation, uncertainty quantification, and professional oversight. However, there are some repeated specifications (e.g., SPEC 3 and SPEC 7), which slightly detract from overall cohesion.",
      "coverage": "The group covers a broad range of critical areas in healthcare decision support, including oncology, vulnerable populations, controlled substances, and emergency situations. It balances general principles with specific edge-case protections, such as the handling of experimental treatments and psychiatric medication management. However, there could be more foundational rules to ensure comprehensive coverage across all healthcare domains.",
      "redundancy": "There is some redundancy in the specifications, such as the repetition of similar requirements (e.g., SPEC 3 and SPEC 7, SPEC 9 and SPEC 15). While redundancy can be beneficial for critical safety areas, these duplications could be consolidated to improve efficiency without losing robustness.",
      "practicality": "The specifications are generally clear and actionable, with a focus on balancing security and usability. They are adaptable to different contexts, such as varying patient populations and medical scenarios. However, some rules are quite specific, which may limit their applicability in broader contexts. Overall, the policy set is implementable and maintainable in real-world scenarios."
    },
    "total_score": 82,
    "temperature": 0.1,
    "max_tokens": 800
  },
  "final_group_scores": {
    "cohesion": 25,
    "coverage": 22,
    "redundancy": 18,
    "practicality": 17
  },
  "total_group_score": 82
}